Gil has been blowing smoke since the company went public in 2007. He is a scientist and a cheerleader, not a businessman. If they want to get Multistem to the finish line, they need to sell the business to a larger firm with resources and the ability to fund the research. At that point, they can concentrate on the science. The days of this being a lottery ticket, at least in the very near future, are gone. Stop making excuses for this debacle of a management team.
Anything to put this project under different management.. After five years, I have concluded that this may be the worst management team in any biotech going. But, just watch..they will get their bonuses in June. Any management team with any conscience would be turning them down.
Siesta: I have communicated with him privately. He still holds his shares. For what it is worth, he has a very severe medical issue. Now, you can do whatever you want, but how about letting this go?
Thanks, Al. I appreciate that. I am honestly more conflicted by this stock than any I have ever owned. Like yourself, I have tied money up in this for a long time without any return, and it is money that missed a huge general market run up. I hear that little voice saying, "Cut the cord and move on", but it always seems like there is another reason to stick around.
I liked the conference call yesterday, but whether anybody likes it or not, I have been listening to GvB's schtick for so long now that I am tired of hearing him (like the market does). I truly hope they can show Multistem works for stroke and other indications, and that I live long enough to see it... All the best to you..
I mentioned this yesterday, doc... at this point, the market is not listening to Gil vanBokkelen. The market responds to results, not just optimism, and so far he hasn't been able to get them. The conference call gave some very optimistic clues for the future, and there is certainly a path here to getting this done to treat stroke. The share price will move with results or partnership (Chugai) news, not on words. There is very good reason to expect an upside, but not in the near term.
I know this: If I have a stroke, I want everything they can throw at me as soon as possible- ESPECIALLY a bag of Multistem.
Thanks, Dale. That is greatly appreciated. I am still a major believer in Multistem and the potential it has to do as both a therapeutic game-changer and as a great investment. However, I have beaten my head against the wall for five years watching this management team. In baseball, this would be the team that can lead for seven innings and never close it out. Even if I end up selling, I sincerely hope they are successful and the stock goes to $100, but there does have to be a place that one has to move on, and I am close to that place. Thanks again, Dale. All the best to you one way or another.
I am sincerely hoping to be wrong, but my expectations for this conference call are very low. At this point, short of announcing a takeover (not), a new merger (not), or that Chugai will be giving them money ( they have said they need three months to analyze the data, I don't expect much to come of this.
The truth of the matter is that, at this point, the market will shrug off anything that Gil van Bokkelen says. Look at how low the institutional investment (the "smart" money) is in this. In 20 years as a company, and 8 as a publicly traded company, there still is nothing substantial or marketable to show. There have been two trials that have missed the mark- UC, which was primarily on Pfizer, and the Stroke trial. Although this did not meet the primary end points, I really do believe there is enough there to create a scenario for success for addressing strokes. That said, one of the key components of investing is investor confidence. At this point, this company has a small flame burning, but is far from being a raging fire.
I have had a lot of money tied up in this since June, 2010. In doing so, that money missed being in one of the strongest bull markets in history, with very little return. Tomorrow, after hearing what has to be said today, I will either be buying more ATHX or selling all that I have. Best of luck to all who remain long.
If this stock is going to move, it is going to move with Dr. Mays presentation today. Regardless of what GvB and others may think, Dr. Mays IS Athersys. There is no one who can get this figured out and on the right track better than he can.
Was he doing something today, or did that get bagged with the shareholder conference being held on Wednesday? If so, any news? (If good, it is not being reflected in the share price).
Thumbs up to this post. Actually, the trial was not a failure- it showed efficacy in a time frame, at least as far as what we have been shown so far. Only complaint about the whole thing is that some people had early information. Other than that, the results created a template for a new trial, and if this template is followed, this will be successful. Only question for long term investors is how much longer we want to tie our money up in this.....unless Chugai moves forward.
Excellent post. And if I could add, making it an Open Label trial would make it more inclusive to reduce the time needed to get the sample size for the trial. With the previous P2 trial, numbers were already generated those who received a placebo.
The leak was leaked to privileged individuals or firms. If there is ever an investigation, it will reveal which firms or individuals were able to sell with this information.